1. Home /
    2. Altai Protocol Library /
  2. New İndication: Cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM)

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New İndication: Cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM)

New İndication: Cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM)
Study:
  • Phase III, randomized, controlled, multicenter study (IND227)
  • Previously untreated, unresectable PM
  • CP + pembrolizumab (n=222) vs. CP (n=218)
Efficacy:
  • mOS: 17.3 vs 16.1 mos, HR:0.79, p=0.0324
  • mPFS: 7.13 vs 7.16 mos, HR:0.80, p=0.0372
  • BOR: 63% vs 40%, p<0.0001
Safety:
  • Grade≥3 irAEs: fatigue (5%), diarrhea (2%), pneumonitis (2%)

Journal of Clin Oncol 2023 41:17_suppl, LBA8505-LBA8505

Chu SQ et al. IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.

http://doi.org/10.1200/JCO.2023.41.17_suppl.LBA8505

Reviewed by Elvin CHALABİYEV, MD on JUN 10, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More